STANFORD UNIVERSITY

Arc Institute adds seven leading scientists to its Investigator Program and Ignite Award cohorts, focusing on complex human diseases. Applications for 2025 Investigator and Fellow programs are open.

U-M's TOPMed Informatics Research Center receives $30M to enhance genetic data usability, focusing on heart, lung, blood, and sleep disorders, aiming to accelerate precision medicine research.

Pheast partnered with Lonza for PHST001 manufacturing, enabling clinical trial supply. PHST001 targets CD24, a 'don’t eat me' signal in cancers. Pheast’s origins trace to Amira Barkal’s research at Stanford, leading to CD24’s therapeutic development. CD24 differs from CD47, offering a more potent effect. Pheast’s discovery process involved diverse models, resulting in a suitable clone. The company looks to CD47 programs for scaling guidance but acknowledges dosing uncertainties. Protein engineering efforts yielded a well-expressed antibody, positioning Pheast for clinical demands.

U-M's TOPMed Informatics Research Center receives $30M to enhance usability of genetic and genomic health data, aiming to advance precision medicine by making data more accessible and meaningful for researchers and healthcare providers worldwide.

The nanomedicine market was valued at USD 223.6 billion in 2023 and is projected to reach USD 634.2 billion by 2032, with a CAGR of 12.2%. This growth is driven by increased demand for advanced drug delivery systems and rising chronic disease incidence. North America leads the market, while Asia-Pacific is expected to grow the fastest.

The nanomedicine market, valued at USD 223.6 billion in 2023, is projected to reach USD 634.2 billion by 2032, driven by advanced drug delivery systems and rising chronic diseases. Key players include Johnson & Johnson, Mallinckrodt Pharmaceuticals, and Teva Pharmaceutical Industries. Recent developments include Novartis's nanoparticle-based ovarian cancer treatment and Merck's partnership with Stanford for immunotherapy research.

Elon Musk's Tesla unveiling of autonomous vehicles and robots faced negative reactions, with stock dropping 9%, highlighting concerns about Tesla's late entry into autonomous tech and Musk's overoptimistic timelines. The event underscored the importance of trust in innovation, emphasizing that successful adoption requires making new products familiar and aligning them with trusted sources.

UC Berkeley scientists used AI and iNaturalist data to create detailed maps of California plant species distribution, predicting the range of 2,221 species with high accuracy.

CAPE received a State of California Joint Resolution for its 20th anniversary, recognizing its contributions to fetal, neonatal, pediatric, and obstetric sciences. Dr. Louis P. Halamek, founding director of CAPE, was also acknowledged.

ARS Pharmaceuticals introduces Neffy, a needle-free epinephrine nasal spray for treating severe allergic reactions, approved by the FDA. Aimed at reducing fear and hesitation associated with EpiPen injections, Neffy offers a simpler, quicker administration method, potentially improving treatment accessibility for millions.